MK-6913
Phase 2Small molecule
Merck & Co.MK-6913 is one of 44 small molecule programs targeting Hot flashes. It is currently in Phase 2.
1
Indications
1
Total Trials
0
Active Trials
43
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
55 competitors in Hot Flashes
#DrugCompanyPhaseTrials
1Lupron
AbbVieApproved
Nolvadex
AstraZenecaApproved
Veozah
AstellasPhase 3
Ambien
PPurdue Pharma LP
Approved
Nitrostat
VViatris Specialty LLC
Approved
Orserdu
SStemline Therapeutics, Inc.
Approved
Depo-Provera
PfizerPhase 3
Depo-Provera
Eli LillyPhase 3
Neurontin
VViatris Specialty LLC
Phase 3
Megace
Bristol-Myers SquibbPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for MK-6913. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company